Hu P - Search Results

1

Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study.

Shi Y, Han X, Zhao Q, Zheng Y, Chen J, Yu X, Fang J, Liu Y, Huang D, Liu T, Shen H, Luo S, Yu H, Cao Y, Zhang X, Hu P. Shi Y, et al. Among authors: hu p. Exp Hematol Oncol. 2024 Jun 12;13(1):60. doi: 10.1186/s40164-024-00528-0. Exp Hematol Oncol. 2024. PMID: 38867257 Free PMC article.

2

First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.

Hu X, Zheng X, Yang S, Wang L, Hao X, Cui X, Ding L, Mao L, Hu P, Shi Y. Hu X, et al. Among authors: hu p. J Hematol Oncol. 2020 Jan 16;13(1):6. doi: 10.1186/s13045-019-0834-2. J Hematol Oncol. 2020. PMID: 31948451 Free PMC article. Clinical Trial.

3

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma.

Zhao Q, Wang T, Wang H, Cui C, Zhong W, Fu D, Xi W, Si L, Guo J, Cheng Y, Tian H, Hu P. Zhao Q, et al. Among authors: hu p. Front Pharmacol. 2022 Nov 1;13:1039416. doi: 10.3389/fphar.2022.1039416. eCollection 2022. Front Pharmacol. 2022. PMID: 36386136 Free PMC article.

4

Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study.

Chen X, Zhao Q, Jiang J, Liu J, Hu P. Chen X, et al. Among authors: hu p. Clin Drug Investig. 2016 May;36(5):369-76. doi: 10.1007/s40261-016-0380-4. Clin Drug Investig. 2016. PMID: 26951202 Clinical Trial.

5

Effects of four traditional Chinese medicines on the pharmacokinetics of simvastatin.

Zhao Q, Jiang J, Hu P. Zhao Q, et al. Among authors: hu p. Xenobiotica. 2015;45(9):803-10. doi: 10.3109/00498254.2015.1019593. Epub 2015 Jul 27. Xenobiotica. 2015. PMID: 25801058 Clinical Trial.

6

CX1003 quantification by ultra-performance LC-MS/MS in human plasma and its application to a pharmacokinetic study in solid tumor patients.

Li Y, Zhao Q, Hu P, Jiang J. Li Y, et al. Among authors: hu p. Bioanalysis. 2019 Aug;11(16):1483-1493. doi: 10.4155/bio-2019-0096. Epub 2019 Sep 3. Bioanalysis. 2019. PMID: 31478754

7

Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects.

Zhao Q, Jiang J, Li X, Lu ZS, Hu P. Zhao Q, et al. Among authors: hu p. Br J Clin Pharmacol. 2007 May;63(5):614-7. doi: 10.1111/j.1365-2125.2006.02782.x. Epub 2007 Feb 26. Br J Clin Pharmacol. 2007. PMID: 17324224 Free PMC article. Clinical Trial.

8

Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.

Hu P, Chen J, Liu D, Zheng X, Zhao Q, Jiang J. Hu P, et al. Eur J Clin Pharmacol. 2015 Jul;71(7):843-50. doi: 10.1007/s00228-015-1864-5. Epub 2015 May 21. Eur J Clin Pharmacol. 2015. PMID: 25995169 Clinical Trial.

9

Development and validation of a UPLC-MS/MS method for simultaneous determination of fotagliptin and its two major metabolites in human plasma and urine.

Wang Z, Jiang J, Hu P, Zhao Q. Wang Z, et al. Among authors: hu p. Bioanalysis. 2017 Feb;9(4):381-393. doi: 10.4155/bio-2016-0243. Epub 2017 Jan 19. Bioanalysis. 2017. PMID: 28102710

10

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.

Wang X, Luo Z, Chen J, Chen Y, Ji D, Fan L, Chen L, Zhao Q, Hu P, Sun P, Jia Z, Guo J, Si L. Wang X, et al. Among authors: hu p. BMC Med. 2023 Jan 4;21(1):2. doi: 10.1186/s12916-022-02669-7. BMC Med. 2023. PMID: 36600247 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,987 results

Search Page

Filters